Navigation Links
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Date:2/24/2011

news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation (NYSE: ... call on Tuesday, August 5, 2014, at 8:30 a.m. ... quarter 2014 financial results. An audio webcast ... the Investor Relations portion of the CVS Caremark website ... http://info.cvscaremark.com/investors . This webcast will be archived and ...
(Date:7/25/2014)... , July 25, 2014 Cardinal Health will ... pharmacies as winners of its prestigious Independent Pharmacy Best ... , one of the nation,s largest gatherings of independent ... – family-owned pharmacies from Ohio , ... – were selected for implementing exceptionally creative ...
(Date:7/25/2014)... , July 25, 2014 According ... Research "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, ... Size, Share, Growth, Trends and Forecast (Value and Volume), ... at USD 19.99 billion in 2012 and is expected ... to 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 2Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 3Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 4Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 5Cardinal Health Announces Three Best Practice Winners for Leading Change in Community Pharmacy 6Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ... today announced the filing of its annual report on ... 2011 with the U.S. Securities and Exchange Commission (the ... financial statements for the fiscal year ended March 31, ...
... July 18, 2011 Scientists at Osel Inc ... have developed a new way to prevent HIV infection ... bacteria to block viral transmission. Bioengineered bacteria introduced into ... the transmission of simian HIV (SHIV) by nearly two ...
Cached Medicine Technology:China Medical Technologies Announces the Filing of its Annual Report on Form 20-F for the Fiscal Year Ended March 31, 2011 with the SEC 2Scientists Use Live Bacteria to Fight HIV 2Scientists Use Live Bacteria to Fight HIV 3
(Date:7/25/2014)... July 25, 2014 On July ... Nuanced Media client and the nation’s number one ... employee handbooks, announced their partnership with TransAct Merchant ... a registered ISO/MSP of Chase Paymentech Solutions, LLC, ... processing industry. Companies that are members of TransAct’s ...
(Date:7/25/2014)... AZ (PRWEB) July 25, 2014 Hastings ... offering discount attorney’s fees with regard to personal ... Hastings provide a wide range of legal services for ... the negligence of another individual or corporation. Free initial ... determining the validity of a potential personal injury ...
(Date:7/25/2014)... Shift workers, especially men, may be at higher risk for ... a new study suggests. Also at special risk are ... shifts moving around at various times of the day. ... Dr. Alan Manevitz, a clinical psychiatrist at Lenox Hill Hospital ... working shifts disrupts many key body chemicals, creating a ripple ...
(Date:7/25/2014)... protect vulnerable neurons and reduce motor deficits in ... Emory University School of Medicine have shown. , ... of Parkinson,s Disease . , The findings demonstrate ... brain at sufficient levels and have beneficial effects ... shot. Previous studies of XPro1595 in animals tested ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Newyorktermlifeinsurance.org ... exam life insurance plans and traditional policies. , ... confusions clients make between no medical exam life insurance ... two types of life insurance plans to provide a ... exam life insurance plans can now be purchased online. ...
Breaking Medicine News(10 mins):Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2
... A number of biological, societal, and health carerelated issues ... with kidney disease, according to two articles appearing in ... American Society Nephrology (JASN). The articles indicate that immediate ... needed to provide better health care for affected Americans. ...
... Next ... 14 Years, ANCHORAGE, ... successfully transitioned all of its rural,telecommunication services last night to the Galaxy ... rural Alaska for the next 14 years., "The success of last ...
... Utilize Strategic Intelligence and Competitive Analysis, from Thomson Reuters to ... on Medical Research and the U.S. Generics ... ... June 4 Thomson Reuters, the,world,s leading source of intelligent information ...
... Company,s DSU Products offer biologically safe water through point-of-use ... ... June 3 Nephros, Inc., a medical,device company, announced today ... the Association for Professionals in Infection,Control and Epidemiology (APIC) conference ...
... Trains Interventional Cardiologists to Stop Strokes, WASHINGTON, ... stroke, every,second counts in saving brain tissue and ... are learning to capture and,remove blood clots in ... treatments used to stop a heart attack. To ...
... 3 Most of us take sleeping safely ... ever slept in a bunk bed, the,safe part ... thing., Listen to this report from Nationwide ... can access video, audio, text, graphics and,photos for ...
Cached Medicine News:Health News:Racial disparities in the outcomes of patients with chronic kidney disease abound 2Health News:Racial disparities in the outcomes of patients with chronic kidney disease abound 3Health News:GCI Successfully Transitions All Traffic to Galaxy 18 Satellite 2Health News:The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline 2Health News:The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline 3Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 2Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 3Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 4Health News:Unique Simulation Training Course Ushers in New Era of Stroke Intervention 2Health News:Unique Simulation Training Course Ushers in New Era of Stroke Intervention 3Health News:Unique Simulation Training Course Ushers in New Era of Stroke Intervention 4
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
... POPmesh is a ... that can be used ... pelvic floor procedures, including ... prolapse. Supple yet strong, ...
... Hydrix XM is a biological ... a material known for excellent ... and manufacturing procedures ensure high ... Caldera's patented processing enhances the ...
FasLata® Allograft Tissue delivers the durability of natural tissue with all the corresponding benefits of ingrowth and natural adaptation to surrounding tissues....
Medicine Products: